Federated Hermes Inc. Has $2.17 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Federated Hermes Inc. cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 24.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 129,164 shares of the biopharmaceutical company’s stock after selling 41,844 shares during the quarter. Federated Hermes Inc.’s holdings in Catalyst Pharmaceuticals were worth $2,171,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. State Board of Administration of Florida Retirement System grew its position in shares of Catalyst Pharmaceuticals by 4.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 1,290 shares during the period. Teacher Retirement System of Texas lifted its stake in Catalyst Pharmaceuticals by 5.3% in the 3rd quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock valued at $335,000 after acquiring an additional 1,456 shares in the last quarter. Cerity Partners LLC lifted its stake in Catalyst Pharmaceuticals by 11.5% in the 4th quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 1,780 shares in the last quarter. Raymond James & Associates lifted its stake in Catalyst Pharmaceuticals by 4.2% in the 4th quarter. Raymond James & Associates now owns 50,279 shares of the biopharmaceutical company’s stock valued at $845,000 after acquiring an additional 2,045 shares in the last quarter. Finally, CenterBook Partners LP lifted its stake in Catalyst Pharmaceuticals by 20.0% in the 3rd quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 2,259 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 12.10% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Stock Up 1.4 %

Shares of CPRX stock opened at $14.89 on Monday. The company has a market cap of $1.76 billion, a P/E ratio of 24.41, a P/E/G ratio of 0.82 and a beta of 0.89. The business has a fifty day simple moving average of $15.54 and a 200 day simple moving average of $14.64. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.09 and a twelve month high of $17.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The company had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. As a group, equities research analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on CPRX shares. Bank of America started coverage on Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They issued a “buy” rating and a $23.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. Finally, Oppenheimer reiterated an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Wednesday, March 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $26.43.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.